Original Article

Digestive Diseases and Sciences

, Volume 58, Issue 6, pp 1790-1796

Thrombocytosis and Hepatocellular Carcinoma

  • Brian I. CarrAffiliated withDepartment of Nutritional Carcinogenesis, IRCCS “S. de Bellis”, National Institute for Digestive DiseasesDepartment of Epidemiology, IRCCS “S. de Bellis”, National Institute for Digestive Diseases Email author 
  • , Vito GuerraAffiliated withDepartment of Nutritional Carcinogenesis, IRCCS “S. de Bellis”, National Institute for Digestive DiseasesDepartment of Epidemiology, IRCCS “S. de Bellis”, National Institute for Digestive Diseases

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Background

Thrombocytopenia has been reported to be both a risk factor for hepatocellular carcinoma (HCC) development as well as a prognostic factor. Many HCCs also occur in presence of normal platelets.

Aim

To examine a cohort of HCC patients with associated thrombocytosis.

Methods

Records were examined of a cohort of 634 biopsy-proven and randomly presenting HCC patients without thrombocytopenia.

Results

In the total cohort, 52 patients were identified with thrombocytosis (platelet levels >400 × 109/L) and compared with 582 patients with normal platelet values. The average tumor sizes were 13.1 versus 8.8 cm (p < 0.0001), and their total average bilirubin levels were 0.9 versus 1.5 (p = 0.02), comparing thrombocytosis patients versus normal platelet count HCC patients. These differences were even more pronounced in patients with HCC sizes >5 cm. Thrombocytosis patients were younger and had less cirrhosis, but similar percent with hepatitis B or C or alcohol consumption.

Conclusion

Thrombocytosis in association with HCC occurs in patients with larger tumor sizes and better liver function.

Keywords

HCC Size Thrombocytosis Portal vein thrombosis